Does size matter? : bridging and dose selection in paediatric trials by Cella, M.
Does size matter? Bridging and dose selection in paediatric trials
Massimo Cella
Ph.D. Thesis, Leiden University, October 2011

Does size matter?
Bridging and dose selection in paediatric trials
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties




geboren te Lodi, Italië
in 1978
Promotor : Prof. dr. M. Danhof
Co-promotor : Dr. O.E. Della Pasqua
Referent : Prof. dr. E.M. Jacqz-Aigrain (Pharmacologie Pédiatrique
et Pharmacogénétique, Hôpital Robert Debré, Paris)
Overige Leden : Prof. dr. A. Cohen
Prof. dr. C.A. Knibbe
Prof. dr. A.P. IJzerman
Prof. dr. M. Sturkenboom (Erasmus MC, Rotterdam)
“He who is certain he knows the ending of things when he is only beginning them is
either extremely wise or extremely foolish; no matter which is true, he is certainly
an unhappy man, for he has put a knife in the heart of wonder”
Tad Williams
a Claudia
The research presented in this thesis was made possible by a Worldwide Development
Fellowship for Post-graduate Training in Clinical Pharmacology and Discovery
Medicine from GlaxoSmithKline and was performed at the Division of Pharmacology
of the Leiden-Amsterdam Center for Drug Research, Leiden University, Leiden,
The Netherlands.
The printing of this thesis was financially supported by:
GlaxoSmithKline
Leiden-Amsterdam Center for Drug Research
Cover design by Stefano Canti, engraving by Gustave Doré (David slays Goliath)
Typeset in LATEX2ε
Printed by Optima Grafische Communicatie, Rotterdam, The Netherlands
ISBN: 978-94-6169-123-1
©2011 Massimo Cella (massimocella@hotmail.com)
No part of this thesis may be reproduced or transmitted in any form or by any




1 General introduction: what is the right dose for children? 13
1.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Current paediatric prescription practice . . . . . . . . . . . . . . . . . 14
The correlation between dose and demographic covariates is not linear 15
Scaling for function, not for size . . . . . . . . . . . . . . . . . . . . . . 16
The future . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
1.2 Model-based paediatric drug development:
regulatory and methodological aspects . . . . . . . . . . . . . . . . . . 20
Bridging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Allometry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
Non-linear mixed effects modelling . . . . . . . . . . . . . . . . . . . . 27
Analysis of pharmacokinetic data . . . . . . . . . . . . . . . . . . . . . 30
Clinical trial simulation . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2 Scope and intent of investigation 47
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
2.2 Parameter estimation and uncertainty . . . . . . . . . . . . . . . . . . 51
2.3 Protocol implementation and trial design factors in paediatric trials 55
2.4 Conclusions and perspectives . . . . . . . . . . . . . . . . . . . . . . . . 58
II Bridging and dosing recommendations for paedi-
atric indications 61
3 Optimisation of PK studies in children: a non-linear mixed
effects approach 63
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
3.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
One-compartment, intravenous administration . . . . . . . . . . . . . 67
One-compartment, oral absorption . . . . . . . . . . . . . . . . . . . . 68
Two-compartment, oral absorption . . . . . . . . . . . . . . . . . . . . 68
One-compartment with saturable elimination, oral absorption . . . . 69
Parameter estimation and model diagnostics . . . . . . . . . . . . . . 69
Optimisation of sampling frequency and intervals . . . . . . . . . . . 70
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
One-compartment, intravenous administration . . . . . . . . . . . . . 71
One-compartment, oral absorption . . . . . . . . . . . . . . . . . . . . 72
Two-compartments, oral absorption . . . . . . . . . . . . . . . . . . . . 73
One-compartment with metabolic saturation, oral absorption . . . . 75
Difference between FO and FOCE methods . . . . . . . . . . . . . . . 76
3.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
4 A model-based approach to dose selection in paediatric devel-
opment 83
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
4.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
Clinical studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
Pharmacokinetic analysis . . . . . . . . . . . . . . . . . . . . . . . . . . 86
Model evaluation and predictive performance . . . . . . . . . . . . . . 88
Rationale for dosing regimen . . . . . . . . . . . . . . . . . . . . . . . . 88
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
Pharmacokinetic analysis . . . . . . . . . . . . . . . . . . . . . . . . . . 89
Clinical relevance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
5 Are population models predictive of PK across populations? 103
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
5.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
Pharmacokinetic analysis . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Evaluating predictive power . . . . . . . . . . . . . . . . . . . . . . . . 107
5.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
PK model in children (Mod1 ) . . . . . . . . . . . . . . . . . . . . . . . 109
PK model in infants and toddlers (Mod2 ) . . . . . . . . . . . . . . . . 110
Extrapolation from children to infants and toddlers . . . . . . . . . . 111
Extrapolation from infants and toddlers to children . . . . . . . . . . 113
5.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
Bridging strategies and model-based dose selection . . . . . . . . . . 113
Differences in parameter-covariate correlations . . . . . . . . . . . . . 116
6 The lack of interpolative power of allometric models 123
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
6.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
Pharmacokinetic analysis . . . . . . . . . . . . . . . . . . . . . . . . . . 127
Prediction of pharmacokinetics in children and adolescents . . . . . . 129
6.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
PK model in infants, toddlers and adults (model 1 ) . . . . . . . . . . 129
PK model in children and adolescents (model 2 ) . . . . . . . . . . . . 131
Interpolation of midazolam exposure from infants, toddlers and
adults to children and adolescents . . . . . . . . . . . . . . . . 132
6.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
7 Dosing rationale for fixed-dose combinations in children 145
7.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
7.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
Clinical studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
Pharmacokinetic analysis . . . . . . . . . . . . . . . . . . . . . . . . . . 148
Pharmacokinetic and covariate model building . . . . . . . . . . . . . 149
Rationale for dosing regimen and choice of the dose ratio . . . . . . . 151
7.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151
Pharmacokinetic analysis (adult data) . . . . . . . . . . . . . . . . . . 151
Pharmacokinetic analysis (pooled data) . . . . . . . . . . . . . . . . . 152
Simulation scenarios and dosing recommendations . . . . . . . . . . . 154
7.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
III Implementation and design of paediatric trials 163
8 Dealing with heterogeneity and uncertainty in PK trials in chil-
dren 165
8.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
8.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
Rationale for the target exposure . . . . . . . . . . . . . . . . . . . . . 168
Pharmacokinetic model . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
Clinical trial simulation . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
8.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171
8.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173
9 Bridging strategies for drug combinations in paediatric indica-
tions 183
9.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184
9.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186
Clinical studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186
Pharmacokinetic analysis . . . . . . . . . . . . . . . . . . . . . . . . . . 186
Clinical Trial Simulation (CTS) . . . . . . . . . . . . . . . . . . . . . . 188
9.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190
Pharmacokinetic analysis . . . . . . . . . . . . . . . . . . . . . . . . . . 190
Clinical Trial Simulation . . . . . . . . . . . . . . . . . . . . . . . . . . 191
9.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196
IV Conclusions and perspectives 205
10 Summary, conclusions and perspectives 207
10.1 Regulatory framework and challenges in the transition from retro-
spective to prospective assessment of medicines for children. . . . . . 207
10.2 Parameter estimation and uncertainty . . . . . . . . . . . . . . . . . . 209
10.3 Protocol implementation and trial design factors in paediatric trials 213
10.4 Perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215
11 Nederlandse samenvatting (Synopsis in Dutch) 221
11.1 Introductie . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223
11.2 Parameterschatting en onzekerheid . . . . . . . . . . . . . . . . . . . . 223
11.3 Adaptatieve protocollen en andere factoren in studieontwerp bij
pediatrisch onderzoek . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
11.4 Conclusie en perspectief . . . . . . . . . . . . . . . . . . . . . . . . . . . 229
Acknowledgements 231
Curriculum vitæ 233
List of publications 235
